Gil M. Labrucherie
2020
In 2020, Gil M. Labrucherie earned a total compensation of $5.3M as Chief Operating Officer and Chief Financial Officer at Nektar Therapeutics, a 29% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $721,000 |
|---|---|
| Option Awards | $1,501,672 |
| Salary | $788,000 |
| Stock Awards | $2,247,676 |
| Other | $27,574 |
| Total | $5,285,922 |
Labrucherie received $2.2M in stock awards, accounting for 43% of the total pay in 2020.
Labrucherie also received $721K in non-equity incentive plan, $1.5M in option awards, $788K in salary and $27.6K in other compensation.
Rankings
In 2020, Gil M. Labrucherie's compensation ranked 2,065th out of 13,090 executives tracked by ExecPay. In other words, Labrucherie earned more than 84.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,065 out of 13,090 | 84th |
Division Manufacturing | 795 out of 5,621 | 86th |
Major group Chemicals And Allied Products | 284 out of 2,254 | 87th |
Industry group Drugs | 240 out of 1,954 | 88th |
Industry Pharmaceutical Preparations | 169 out of 1,459 | 88th |
Source: SEC filing on April 30, 2021.
Labrucherie's colleagues
We found four more compensation records of executives who worked with Gil M. Labrucherie at Nektar Therapeutics in 2020.